Skip to content

Bold science in drug discovery
and development

Gubra is a disease-agnostic bioscience company with deep expertise in peptide drug discovery and preclinical research services, built around a differentiated innovation model

We use our proprietary AI-based peptide drug discovery platform to advance high-value assets toward clinical proof of concept

We build asset-centric biotech ventures around externally sourced opportunities, leveraging Gubra’s scientific expertise and shared infrastructure

CRO

We provide preclinical research services that help pharmaceutical and biotech companies accelerate their drug development pipelines

Stock information

Listen to recent
earnings call

CEO interview

Read Gubra’s
Interim Report Q2 2026

Download report

See Gubra’s
Corporate Presentation

Download presentation

Latest news

Gubra outlines 2030 strategy to scale innovation and expand its clinical-stage pipeline

REMINDER: Gubra Investor R&D Event on October 27, 2026

Gubra’s partner AbbVie presents detailed Phase 1 data for ABBV-295, a long-acting amylin analog, demonstrating favorable tolerability and pharmacokinetic profile at EASD 2026

Gubra Green

Giving back
to nature

Gubra Green is Gubra’s dedicated business unit for investing beyond our own footprint. We allocate 10% of our pre-tax profits to solar energy and nature restoration

Gubra Green invests to create measurable progress and impact on climate and nature.

850+ ha

Land under restoration
Across Langeland, Hem Skov and Understed Bakker

175M

DKK Portfolio investments
Since 2020

4

Portfolio investments
across land, nature restoration and green energy

Careers

Work with us…

I was driven towards Gubra because of the fact that our efforts might help improve patients’ lives ”

Mads Mørup Nygaard
Senior Department Manager

I like the mix of practical work in the laboratory and data analysis at the computer ”

Yessica Wouters Van-Looy
PhD, Senior Scientist

For further information

Contact us

Back To Top